BioSpace News Archive

Bracco Imaging announced that the American College of Radiology has classified VUEWAY® as a Group II agent within its classification of gadolinium-based contrast agents relative to the risk of development of nephrogenic systemic fibrosis.2

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced it will present investigational research and exhibit at the 26th American Society of Gene and Cell Therapy being held in Los Angeles, CA from May 16 to May 20.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its first quarter 2023 financial results and provided a business update.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update.

Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ended March 31, 2023 and provides a business update.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced financial results for the first quarter ended March 31, 2023.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced financial results for the first quarter ended March 31, 2023, and updated 2023 revenue guidance.

Atreca, Inc. (Atreca) (NASDAQ: BCEL) today announced financial results for the first quarter ended March 31, 2023 and provided an overview of recent developments.

Icosavax, Inc. (Nasdaq: ICVX) today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and first-quarter 2023 financial results.